Font Size:
A Phase 2 Randomized, Placebo-Controlled Trial of Tideglusib, an Orally Administered GSK3Beta Inhibitor, in the Treatment of Adolescents with Autism Spectrum Disorder
Last modified: 2018-09-15
Abstract
Conclusions: This clinical trial successfullyestablished proof-of-concept that tideglusib, a GSK3 beta inhibitor, merits further study as a potentialtreatment for ASD.
Conference registration is required in order to view papers.